Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.

Abstract

The pharmacokinetics of 20 mg torasemide i.v. has been studied in 7 healthy controls and 9 patients with varying degrees of renal impairment. Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance. The active metabolite M 1 and the main metabolite M 5 were accumulated in chronic renal failure. In contrast to liver function, therefore, kidney failure does not have an important effect on the pharmacokinetics of torasemide.

• Authors: H Spahn, H Knauf, E Mutschler
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 39 Issue 4 Pg. 345-8 ( 1990) ISSN: 0031-6970 [Print] Germany
• PMID: 2076715 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Diuretics
• Sulfonamides
• Torsemide

Topics

• Diuretics (chemistry, pharmacokinetics)
• Half-Life
• Humans
• Kidney (metabolism)
• Kidney Failure, Chronic (metabolism)
• Metabolic Clearance Rate
• Sulfonamides (chemistry, pharmacokinetics)
• Torsemide